KCNT1 Epilepsy Foundation News & Updates

Stay updated with the latest news on KCNT1 epilepsy, including genetic research, drug advancements, patient stories, advocacy efforts, and support for parents.

Raising Awareness in the UK
Sarah Drislane Sarah Drislane

Raising Awareness in the UK

Our parent ambassador, Catherine Holliday, is doing a great job creating awareness for KCNT1. Her family has been featured by numerous media outlets after Action Medical funded a drug repurposing screening in search for KCNT1 inhibitors. We hope to identify a top candidate from the screening to take to clinical trials soon.

Read More
Arpin Strong Selects KCNT1 Foundation
Sarah Drislane Sarah Drislane

Arpin Strong Selects KCNT1 Foundation

We are grateful for the Arpin International Group and Arpin Strong for selecting our charity to support for the month of March. Arpin’s history of giving back to the community is commendable and we are honored to have been selected and supported by all the employees. The entire KCNT1 community says thank you!

Read More
Meet Paddy
Sarah Drislane Sarah Drislane

Meet Paddy

Meet KCNT1 warrior, Paddy and his family.

Read More
AI Based Drug Discovery & Development – Not a long shot anymore
Sarah Drislane Sarah Drislane

AI Based Drug Discovery & Development – Not a long shot anymore

World Pharma Today’s interview by Dhaval Patel, Executive Vice President and Chief Scientific Officer of UCB, a global biopharmaceutical company focused on the discovery and development of novel drugs (including KCNT1) and solutions that have the potential to transform people’s lives. We also go in-depth on how UCB has advanced the field of drug discovery through technological partnerships.

Read More
Pick sunflowers for a donation at Freeling
Sarah Drislane Sarah Drislane

Pick sunflowers for a donation at Freeling

Thanks to the Barns of Freeling for hosting a fundraiser. Over 1,000 people came out to water and pick sunflowers and many made a donation to the KCNT1 Epilepsy Foundation. Thank you to 7News!

Read More
Collaboration between UCB and Praxis for a KCNT1 Small Molecule
Sarah Drislane Sarah Drislane

Collaboration between UCB and Praxis for a KCNT1 Small Molecule

UCB, a global biopharmaceutical company (EURONEXT BRUSSELS: UCB), and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.

Read More
Welcome Stanford GC Interns
Sarah Drislane Sarah Drislane

Welcome Stanford GC Interns

We are grateful to have the support of three interns this summer: Jacqueline Fung, Michaela Taylor, Astrid Torres!

Read More